Science Study Reveals How Phage Proteases Trigger Bacterial CBASS Immunity

Bacteria possess sophisticated antiviral defence systems capable of detecting bacteriophage infection and preventing viruses from spreading through a population. A new study published in Science has now uncovered an unusual mechanism used by one of the most widespread bacterial immune pathways: the bacterium detects infection when a phage enzyme directly modifies a host protein, transforming an essential viral activity into the signal that launches an antiviral response.

The work was carried out by Samuel J. Hobbs, assistant professor of biochemistry at University of Utah Health, and Philip J. Kranzusch, professor of microbiology at Harvard Medical School. Their study, titled “Phage proteases activate CBASS antiphage immunity,” was published on October 1, 2026 and focuses on CBASS, or cyclic oligonucleotide-based antiphage signalling systems, a major family of bacterial defence pathways that can stop phage replication by triggering a powerful intracellular response.

CBASS systems operate through signalling molecules that activate downstream effectors after infection has been detected. In many cases, those effectors severely disrupt the infected bacterium or kill it entirely. Although this response is costly for the individual cell, it can benefit the surrounding bacterial population because a phage that loses its host before completing replication cannot efficiently produce and release new viral particles. This type of population-level defence is often described as abortive infection, in which the infected bacterium sacrifices itself to reduce viral spread.

Such a drastic response requires precise control because accidental activation would be highly detrimental to the bacterium. The central question addressed by Hobbs and Kranzusch was therefore how CBASS distinguishes genuine phage infection from normal cellular activity. Their results show that the bacterial immune system can monitor a biochemical activity that the invading phage itself requires during infection.

Certain bacteriophages encode proteases, enzymes that cleave other proteins and participate in viral replication or maturation. The researchers found that a phage protease directly acts on a bacterial host protein involved in CBASS sensing. This cleavage is not merely collateral damage produced during infection; instead, it becomes the molecular signal that activates the broader CBASS pathway.

The mechanism is particularly interesting because it differs from many familiar antiviral recognition strategies. Numerous immune systems detect viral DNA or RNA as foreign genetic material, whereas the mechanism described in this study responds to an enzymatic event. The bacterium effectively monitors what the phage is doing rather than simply recognizing that foreign nucleic acid is present.

This creates an evolutionary trap for the virus. If the phage requires its protease to complete a successful infection, the bacterium can use that essential enzymatic activity as evidence that viral replication is underway. The phage cannot necessarily escape detection simply by eliminating the protease because doing so could compromise its own life cycle, forcing viral evolution toward more subtle solutions such as modifying substrate recognition, altering protease activity or deploying dedicated anti-defence factors.

The finding also helps explain how CBASS can respond at a specific stage of infection. Instead of triggering immediately when the phage genome enters the cell, the defence system can react once a viral protein begins performing a function associated with productive replication. For an abortive infection pathway, this provides a potential balance between avoiding unnecessary self-destruction and activating quickly enough to prevent the release of progeny phages.

The study therefore adds another layer to the molecular arms race between bacteria and bacteriophages. Bacterial defence systems continuously evolve mechanisms for recognizing viral molecules or activities, while phages evolve ways to avoid detection or suppress immune signalling. A viral protein that is advantageous because it performs an essential replication function can simultaneously become a vulnerability if bacteria evolve sensors capable of recognizing its activity.

This mechanism is especially relevant to phage therapy because bacterial susceptibility to phages depends on much more than receptor recognition. A therapeutic phage may successfully attach to the bacterial surface and inject its genome but still fail to replicate if intracellular defence systems such as CBASS detect the infection and terminate it before viral propagation is complete.

This distinction is becoming increasingly important as researchers attempt to move phage therapy from empirical screening toward more rational selection. Host range is often discussed primarily in terms of bacterial receptors and phage tail fibres, yet intracellular immunity can determine whether an apparently compatible phage–bacterium pair actually results in productive infection. Understanding the defence systems encoded by a clinical bacterial isolate may therefore become increasingly useful when evaluating candidate therapeutic phages.

The discovery could also inform future phage engineering, although the study itself does not demonstrate a therapeutic engineering strategy. If researchers know that a particular phage protease triggers a particular CBASS sensor, they can begin investigating which molecular interaction causes activation and whether naturally occurring phage variants have evolved mechanisms that avoid the response. Such information could eventually help explain why closely related phages display different levels of activity against bacteria carrying the same antiviral system.

Avoiding a single defence pathway would not, however, be sufficient to guarantee therapeutic activity. Bacterial genomes can encode multiple antiphage systems simultaneously, including restriction-modification systems, toxin–antitoxin modules, CRISPR-based defences and many recently discovered systems whose mechanisms are still being characterized. A successful phage must therefore pass through several biological checkpoints before productive infection occurs.

The work is also relevant beyond phage therapy because CBASS belongs to an evolutionarily important family of immune signalling pathways. Related mechanisms are found in animal innate immunity, and the conservation of these signalling principles across large evolutionary distances suggests that they represent ancient and fundamental strategies for detecting viral infection.

Bacterial systems provide particularly useful experimental models for studying these processes because bacterial populations grow quickly and can be genetically manipulated at large scale. Discoveries in bacterial antiviral immunity can therefore reveal general principles of molecular recognition, signal amplification and immune activation that can later be compared with related mechanisms in more complex organisms.

Hobbs emphasized that the persistence of related immune systems across bacteria and humans reflects the evolutionary importance of these pathways. The study therefore contributes both to the mechanistic understanding of bacterial defence and to a broader picture of how cells have evolved to recognize viral threats over billions of years.

For phage biology, the new findings reinforce the idea that infection cannot be understood solely through the physical interaction between a virus and a bacterial surface receptor. Productive infection depends on a sequence of molecular events that continues after genome entry, and bacterial immunity can intervene at multiple stages during that process.

This perspective is becoming increasingly relevant as phage research combines genomics, functional genetics, structural biology and computational prediction. Recent studies have begun identifying previously unknown bacterial defence systems, mapping phage anti-defence genes and predicting phage–host interactions using genomic information. Understanding how individual sensors such as those in CBASS are actually activated provides the mechanistic detail needed to interpret those larger datasets.

The study by Hobbs and Kranzusch offers a particularly clear example of how deeply intertwined phage replication and bacterial immunity can become. The same viral protease that helps the phage complete its infection can also betray the virus by activating the bacterial defence system designed to stop it.

For future phage therapy, such mechanisms could eventually help researchers understand not only which phages bind a bacterial strain, but also which ones can survive the immune environment inside that bacterium. That distinction may prove essential for making phage selection faster, more predictable and more mechanistically informed.

Sources :

University of Utah Health — “Research uncovers how bacteria fight viruses, opening the door to better virus-based antibiotics”
https://healthcare.utah.edu/newsroom/news/2026/10/research-uncovers-how-bacteria-fight-viruses

University of Utah — “Research uncovers how bacteria fight viruses, opening the door to better virus-based antibiotics”
https://attheu.utah.edu/health-medicine/research-uncovers-how-bacteria-fight-viruses-opening-the-door-to-better-virus-based-antibiotics/

Samuel J. Hobbs and Philip J. Kranzusch — “Phage proteases activate CBASS antiphage immunity,” Science
https://www.science.org/doi/10.1126/science.aeg3949